Feedback / Questions
AD-214 - AdAlta
https://www.proactiveinvestors.com.au/companies/news/978778/adalta-finalises-preclinical-development-program-for-inhaled-version-of-anti-fibrotic-drug-ad-214-978778.html
Apr 5, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next